Answers are grounded in this paper and cite their sources.
This review highlights NLRC4’s dual role in cancer, identifying it as a potential biomarker and key target for therapeutic interventions.
• NLRC4 forms an inflammasome complex that controls the development and progression of infection, autoinflammation and cancer. • NLRC4 triggers protective or pathological inflammasome responses and inflammation, reflecting its tumor-attenuating and tumor-promoting roles. • NLRC4 forms novel tumor-attenuating complexes independently of inflammasomes that activate DNA damage responses. • NLRC4 may serve as a biomarker in the prognosis and treatment response for certain cancers. NLRC4 forms an inflammasome complex and activates a critical innate immune response to bacterial infection. The NLRC4 inflammasome triggers the activation of the cysteine protease caspase-1, leading to the proteolytic maturation of the pro-inflammatory cytokines IL-1β and IL-18, and the induction of pyroptosis. The role of NLRC4 in antimicrobial defense is well-established, but emerging evidence highlights a complex and often paradoxical functions of NLRC4 in the development and progression of cancer. NLRC4 acts as a tumor suppressor in colorectal and intestinal cancer, and potentially melanoma. NLRC4 also forms unique tumor-attenuating protein complexes, independently of NAIPs, ASC and caspase-1, that activate the DNA damage response. In obesity-associated cancers and metastasis, NLRC4 is pro-tumorigenic and promotes pathological inflammation and angiogenesis. Understanding the precise regulatory mechanisms of NLRC4 in cancer will provide insights into the development of personalized immunotherapies. This review discusses the multi-functional roles of NLRC4 in cancer and explores the potential clinical utility of targeting NLRC4 in therapies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: